Preclinical studies demonstrating that the FDA-approved ALK inhibitor, crizotinib, also inhibits ROS1 provided rationale for its use in treatment of ROS1+ NSCLC patients [28]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.